RARE on the Road in Salt Lake City, UT
June 18, 2018
Please join us and Global Genes on Saturday, June 30th for RARE on the Road Rare Disease Leadership Tour in Salt Lake City, Utah. This conference will educate rare disease patients, caregivers and other advocates through collaboration in an interactive and engaging environment.
A limited number of $150 travel stipends are available for rare disease patients and caregivers who otherwise would not be able to attend. Please apply here. REMINDER: the deadline to apply for a Salt Lake City travel stipend is May 31st.
Whether you are new to the rare disease community or a seasoned veteran, this full day workshop will help you become a more effective advocate. Topics include:
- Being Seen and Heard: Social Media Strategies to Click and Connect, presented by the Mayo Clinic.
- What’s on the Legislative Road Ahead? Accelerating Change in the Rare Disease Community.
- Detours to Destinations: Navigating Your Rare Disease Landscape.
Join us for this event at the Intermountain Primary Children’s Hospital from 8:30 a.m. through 4:30 p.m. Breakfast, a networking lunch and a t-shirt are included. Sample agenda is available here.
Unable to attend but want to ensure your patient community is present? Let us know and we can provide you with shareable materials to help spread the word! For more information, please visit www.RARETour.org or email lcundiff@everylifefoundation.org.
Thank you to the sponsors of RARE on the Road.
For information on additional sponsorship opportunities, please contact Carol Kennedy at ckennedy@everylifefoundation.org.
Recent News
- Seek Labs Announces Inclusion of Veterinary Diseases in Global Disease Atlas, Accelerating Development of Therapeutics to Bolster Global Protein Supply Chains
- Nestmedic Selects Curavit Clinical Research as U.S. CRO Partner for Pioneering Prenatal Monitoring Trial
- Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions
- BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
- Canary Speech Achieves HITRUST e1 Certification for Voice Biomarker Platform
- Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia